采用Deucravacitinib治疗银屑病关节炎患者后患者报告结局的改善:一项随机2期试验结果
这项2期双盲试验将203例活动性银屑病关节炎患者按1:1:1随机分配至Deucravacitinib 6 mg每日一次、12 mg每日一次或安慰剂组治疗16周。第16周时,两个Deucravacitinib组的HAQ-DI与SF-36 PCS较基线的变化均显著优于安慰剂,且达到最小临床重要差异或恢复正常值的患者比例更高。
要点
- 第16周HAQ-DI较基线变化:6 mg组与安慰剂组差异-0.26(95%CI -0.42至-0.10,P=0.0020),12 mg组差异-0.28(95%CI -0.45至-0.12,P=0.0008)。
- 第16周SF-36 PCS较基线变化:6 mg组与安慰剂组差异3.3(95%CI 0.9至5.7,P=0.0062),12 mg组差异3.5(95%CI 1.1至5.9,P=0.0042)。
- 两个Deucravacitinib剂量组在所有患者报告结局中均报告了最小临床重要差异,且达到最小临床重要差异或恢复正常值的患者比例高于安慰剂组。
核心结论
- Deucravacitinib组在活动性银屑病关节炎患者中较安慰剂组显示出患者报告结局的显著且有临床意义的改善,需进一步研究。
研究设计与样本
- 这项2期双盲试验(NCT03881059)将活动性银屑病关节炎患者按1:1:1随机分配至Deucravacitinib 6 mg每日一次、12 mg每日一次或安慰剂组,治疗16周,共纳入203例患者(51.2%为女性;平均±标准差年龄49.8±13.5岁)。
主要发现
- 第16周HAQ-DI较基线变化的最小二乘均数差(95%CI)vs安慰剂:6 mg组-0.26(-0.42至-0.10),P=0.0020;12 mg组-0.28(-0.45至-0.12),P=0.0008。
- 第16周SF-36 PCS较基线变化的最小二乘均数差(95%CI)vs安慰剂:6 mg组3.3(0.9至5.7),P=0.0062;12 mg组3.5(1.1至5.9),P=0.0042。
- 两个Deucravacitinib剂量组在所有患者报告结局中均报告了第16周的最小临床重要差异。
- 接受Deucravacitinib治疗的患者中报告达到最小临床重要差异或恢复正常值的比例高于安慰剂组。
关键数值与推荐
- 主要次要终点为第16周HAQ-DI和SF-36 PCS较基线的变化。
- 其他患者报告结局评估疾病影响,包括疲劳、疼痛和心理健康。
- 评估了患者报告结局的平均较基线变化以及报告达到最小临床重要差异或评分高于正常值的患者百分比。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective. METHODS: This phase 2, double-blind trial (NCT03881059) randomized patients with active PsA 1:1:1 to deucravacitinib 6 mg once daily (QD), 12 mg QD, or placebo, for 16 weeks. Key secondary end points were changes from baseline (CFBs) at week 16 in Health Assessment Questionnaire-Disability Index (HAQ-DI) and 36-item Short-Form Health Survey (SF-36) physical component summary (PCS) scores. Additional patient-reported outcomes (PROs) assessed disease impact, including fatigue, pain, and mental health. The mean CFBs in PROs and percentages of patients reporting improvements with minimum clinically important differences (MCIDs) or scores of greater than normal values were also assessed. RESULTS: This study comprised 203 patients (51.2% female; mean ± SD age, 49.8 ± 13.5 years). At week 16, the adjusted mean difference (95% confidence interval) versus placebo in HAQ-DI and SF-36 PCS CFB was significant for each deucravacitinib group (HAQ-DI 6 mg, -0.26 [-0.42 to -0.10], P = 0.0020; HAQ-DI 12 mg, -0.28 [-0.45 to -0.12], P = 0.0008; SF-36 PCS 6 mg, 3.3 [0.9 to 5.7], P = 0.0062; SF-36 PCS 12 mg, 3.5 [1.1 to 5.9], P = 0.0042). MCID at week 16 were reported for all PROs with either dose of deucravacitinib. Improvements of MCID or to normative values were reported by more patients receiving deucravacitinib than placebo. CONCLUSION: Deucravacitinib groups demonstrate significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA, which warrants further study.
引用
- Strand V, Gossec L, Coates LC, et al. Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial. Arthritis Care Res (Hoboken). 2024. PMID: 38529674. doi:10.1002/acr.25333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。